Bridgeway Capital Management’s CAMP4 Therapeutics CAMP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$220K Buy
54,378
+29,378
+118% +$121K ﹤0.01% 996
2026
Q2
$109K Hold
25,000
– – ﹤0.01% 1141
2026
Q1
$110K Hold
25,000
– – ﹤0.01% 1117
2025
Q4
$153K Hold
25,000
– – ﹤0.01% 1063
2025
Q3
$75K Hold
25,000
– – ﹤0.01% 1136
2025
Q2
$36.2K Buy
+25,000
New +$49.8K ﹤0.01% 1147

Other funds holding CAMP

Bridgeway Capital Management's CAMP Position: Q3 2026 in Review

Bridgeway Capital Management increased its CAMP4 Therapeutics (CAMP) stake by 118% in Q3 2026, buying an estimated $121K and bringing the position to 54,378 shares worth $220K. The position accounts for ﹤0.01% of the portfolio, ranked #996.

Bridgeway Capital Management first reported a position in CAMP in Q2 2025 and has held it in 6 quarters since. 69 funds tracked by Wall St. Rank hold CAMP as of Q3 2026.

  • Bridgeway Capital Management held 54,378 shares of CAMP4 Therapeutics worth $220K as of Q3 2026.
  • Bridgeway Capital Management bought 29,378 CAMP4 Therapeutics shares in Q3 2026, an estimated $121K.
  • CAMP4 Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #996 holding.
  • Bridgeway Capital Management first reported a position in CAMP4 Therapeutics in Q2 2025 and has held it in 6 quarters since.
  • 69 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q3 2026.

Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.